Gilead is letting go of 34 employees at its Oceanside, California, site.
All entries for: Multiple
January 19, 2026
Takeda
Layoffs
Cambridge, MA
50,001+ employees
Takeda is laying off 243 employees across its U.S. operations, an effort that will heavily affect its neuroscience commercialization teams.The spokesperson told the media outlet the workforce reduction was part of a “strategic decision” to help the company navigate its upcoming loss of exclusivity for Trintellix, a major depressive disorder drug. That decision also includes “reprioritizing resources to prepare for multiple potential new medication launches in the U.S.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
January 8, 2026
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
A month after announcing a partnership with Regeneron to advance its lead gene editor, Tessera Therapeutics has disclosed it will lay off 90 employees. Endpoints News first reported the cuts. Several employees told Endpoints the layoffs will affect about 35% of the workforce. The cuts follow a 17% reduction in 2025 and 13% downsizing in 2024.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
January 3, 2026
GSK
Layoffs
San Francisco, CA
50,001+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK, according to Fierce.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
December 12, 2025
Geron Corporation
Layoffs
Foster City, CA
51-200 employees
In a bid to reinvigorate sales of its cancer therapy Rytelo, Geron is reducing its headcount by a third and said it will use the savings to strengthen its commercial strategy and execution for the drug. The company currently has about 260 employees, so the layoffs will affect about 87 people, according to a Thursday news release.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
December 12, 2025
Pfizer
Layoffs
New York, NY
50,001+ employees
Pfizer will part ways with more than 200 employees across Switzerland as part of a continuing effort to slow its cash burn, according to a report from Bloomberg on Dec. 10. After the layoffs, the pharma expects its Switzerland headcount to shrink to around 70 people, down from 300, the publication noted, citing anonymous sources familiar with the matter.
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 25, 2025
Novartis
Layoffs
Basel, Switzerland
10,001-50,000 employees
Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 18, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck is letting go of 204 employees from its Rahway, New Jersey location, continuing its aggressive layoff spree in recent months.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 13, 2025
Trevi Therapeutics, Inc.
Neutral Outlook
New Haven, CT
1-50 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage.
Disease Area: Multiple, Neurological Diseases, Respiratory
Drug Type: Small Molecule